ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status. [electronic resource]
Producer: 20130830Description: 3683-91 p. digitalISSN:- 1538-7445
- Antineoplastic Agents -- pharmacology
- Ataxia Telangiectasia Mutated Proteins
- BRCA1 Protein -- genetics
- BRCA2 Protein -- genetics
- Benzimidazoles -- pharmacology
- Cell Cycle Proteins -- antagonists & inhibitors
- Cell Line, Tumor
- Cell Survival -- drug effects
- Checkpoint Kinase 1
- Cisplatin -- pharmacology
- Deoxycytidine -- analogs & derivatives
- Dose-Response Relationship, Drug
- Female
- Humans
- Immunoblotting
- Ovarian Neoplasms -- genetics
- Phosphorylation -- drug effects
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases -- metabolism
- Protein Kinases -- genetics
- Protein Serine-Threonine Kinases -- antagonists & inhibitors
- Pyrazines -- pharmacology
- Pyrazoles -- pharmacology
- Pyrimidines -- pharmacology
- RNA Interference
- Signal Transduction -- drug effects
- Sulfones -- pharmacology
- Topotecan -- pharmacology
- cdc25 Phosphatases -- genetics
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.